pexels-photo-5863389.jpeg

COVID-19 vaccine blood clots can be successfully mitigated, study.

New research has shown that early testing for blood clots in patients who had received the AstraZeneca/Oxford vaccine led to them being treated successfully, highlighting the need for heightened awareness of the risk among doctors.

The work, led by researchers from RCSI University of Medicine and Health Sciences and the National Coagulation Centre at St James’s Hospital, is published in the British Journal of Haematology.

Unusual blood clots with low blood platelets have been recognised as a very rare complication of the AstraZeneca vaccine. However, with increased awareness, patients may not have all of these symptoms when they initially present to medical services.


Inability to stand on one leg later in life linked to near doubling of death risk.
Balance test could be included in routine health checks for older adults, …
Hormones are linked with sleep apnea, snoring in postmenopausal women.
Study found an association between obstructive sleep apnea risk and low estrogen …
Soil microbes return after replanting local native plants.
Robust long-term ecosystem restoration relies not just on replanting native vegetation but …
Conversations with Ralph Hruban and Will Linder: Ten medical renegades and “A Scientific Revolution” in America.
HAVE YOUR SAY.Join us in The Bullpen, where the members of the …

The researchers highlighted four patients who had clotting complications induced by the vaccine (Vaccine Induced Thrombotic Thrombocytopenia, VITT). Based on the current guidance, each patient could have been classified as a low likelihood for this syndrome when they presented to doctors, but due to the increased awareness and clinical vigilance from the medical teams involved, all were sent for testing early, diagnosed and treated successfully.

“The risk of developing a blood clot from the vaccine is still far lower than the risk of developing clots from Covid-19, but it is imperative that clinicians are vigilant in detecting symptoms among vaccinated patients,” said Dr Michelle Lavin, the lead author of the paper and researcher at the Irish Centre for Vascular Biology and the RCSI School of Pharmacy and Biomolecular Science.

“Our research has shown that current guidelines lack the sensitivity to detect early cases of vaccine-induced clotting, which could risk missing or delaying diagnoses. As our understanding of this novel condition evolves, heightening our clinical awareness can improve outcomes for patients through early testing and treatment.”

This work is part of the Irish COVID-19 Vasculopathy Study (ICVS), supported by a Health Research Board COVID-19 Rapid Response award and also by a philanthropic grant from the 3M Foundation to RCSI University of Medicine and Health Sciences in support of COVID-19 research. The work was carried out in hospitals in both the Republic of Ireland and Northern Ireland.


Processing…
Success! You're on the list.

Leave a Reply

%d bloggers like this: